Background-Use of bivalirudin has been associated with a reduction in the incidence of bleeding in patients undergoing percutaneous coronary intervention. Patients with chronic kidney disease, a known predictor of post-percutaneous coronary intervention bleeding, are under-represented in clinical trials. Methods and Results-We evaluated the outcome of 64 052 patients who underwent percutaneous coronary intervention from 2007 to 2009 at 33 hospitals in Michigan and were treated with bivalirudin (28 378) or with heparin and glycoprotein IIb/IIIa inhibitors (35 674). Propensity-matched analysis was adjusted for the nonrandomized use of the 2 strategies.
R enal insufficiency is highly prevalent among patients with coronary artery disease. 1 Prior studies suggest that 35% to 40% of patients presenting with an acute coronary syndrome have some degree of renal insufficiency. 2 Patients with chronic kidney disease (CKD) and coronary artery disease are known to have reduced survival and increased incidence of bleeding complications following percutaneous coronary intervention (PCI). 1, 3 This has prompted considerable research to determine the optimal antithrombotic regimen to use in patients with CKD undergoing PCI that will reduce bleeding complications without sacrificing antiischemic activity. 4, 5 Despite their increased risk, patients with more severe degrees of renal dysfunction are often excluded or under-represented in clinical trials. 4, 5 Several randomized controlled trials and observational studies have demonstrated that the use of bivalirudin during PCI is noninferior to heparin plus glycoprotein IIb/IIIa inhibitors (GPIs), with the added benefit of significant reduction in the incidence of bleeding. [6] [7] [8] [9] [10] [11] Post hoc analyses of these trials suggest that the benefits of bivalirudin are preserved in patients with CKD. [12] [13] [14] [15] These analyses have generally excluded patients with advanced CKD, and there remains a paucity of data on the comparative safety and efficacy of bivalirudin versus heparin and GPI use in patients with impaired renal function in real-world practice. The purpose of our study was to evaluate the impact of worsening renal function on the comparative bleeding risk associated with use of bivalirudin versus heparin plus GPIs in a broad and unselected population of patients undergoing PCI using data from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Methods

Data Sources and Study Population
The study population for this analysis comprised consecutive patients undergoing PCI from 2007 to 2009 at 33 hospitals participating in the BMC2. We excluded patients who were on dialysis before undergoing PCI, patients undergoing PCI for cardiogenic shock or cardiac arrest, patients who received fibrinolytic therapy, and patients who died in the catheterization laboratory.
The details of the BMC2 registry and its data collection and auditing process have been described previously. 16, 17 To summarize, BMC2 is a prospective, multicenter registry that collects data from consecutive PCI cases at all nonfederal hospitals in the state of Michigan. Data are collected on all patients undergoing PCI at the participating hospitals using standardized collection forms. This includes clinical, demographic, procedural, and angiographic characteristics as well as medications used before, during, and after the procedure, and inhospital outcomes. All data elements have been prospectively defined, and local institutional review boards at each hospital approved the protocol. In addition to a random audit of 2% of all cases, medical records of all patients undergoing multiple procedures or coronary artery bypass grafting (CABG) and of patients who died in the hospital are reviewed routinely to ensure data accuracy.
Study End Points
Our primary outcomes of interest were need for transfusion, vascular complications, and in-hospital mortality. Our secondary outcomes were gastrointestinal (GI) bleeding, subacute stent thrombosis, need for CABG during the same hospitalization, and stroke or transient ischemic attack. Blood transfusion was defined as any transfusion of blood product regardless of the number of units transfused. Vascular complications included development of hematoma, retroperitoneal hematoma, pseudoaneurysm, arteriovenous fistula, acute thrombosis, need for surgical repair, and loss of limb. Death was defined as mortality from any cause before discharge from the hospital following PCI.
Statistical Analysis
Baseline characteristics are reported as means for continuous variables and as proportions for categorical variables by treatment group. Differences in baseline characteristics between treatment groups were assessed using the χ 2 test for categorical variables and the t test for continuous variables.
The unadjusted analysis included all patients in the study cohort. We used propensity score matching to account for the nonrandom use of bivalirudin and to adjust for possible differences in patient characteristics between the 2 treatment groups. 18 Specifically, the probability (propensity score) of receiving bivalirudin was modeled and estimated using a logistic regression model. Based on the estimated propensity scores, one-to-one matching was then conducted to select patient pairs from the 2 groups with similar propensity scores: only matched pairs were included in the propensity scorematched cohorts.
The patient characteristics adjusted for in the propensity score model included patient demographics: age, sex, race, body mass index; comorbidities: smoking status, history of hypertension, diabetes mellitus, congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, prior myocardial infarction, PCI, CABG; cardiac status: priority (emergent, urgent, nonurgent), staged PCI, salvage PCI, PCI day of catheterization, stable angina, unstable angina, high-risk noncardiac surgery, atypical angina, turned down for CABG; and medications: aspirin, low-molecular-weight heparin, nitrates, vasopressors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, calcium channel blockers, diuretics, statins, warfarin, N-acetylcysteine, and clopidogrel.
To account for the clustering of patients within hospitals, generalized linear models for repeated measures with a logit link were used to model the outcomes on both the entire cohorts and the propensity score-matched cohorts. The risk associated with bivalirudin use was assessed by including an indicator for bivalirudin as a single covariate, and the risk of bivalirudin relative to heparin and GPIs is reported as odds ratios. The degree of renal insufficiency and the treatment by renal insufficiency interaction were further added to the models to evaluate the impact of renal insufficiency. Because of small sample size, the subgroup of patients with glomerular filtration rate (GFR) <15 were excluded from this analysis.
We also assessed differences in an unrelated outcome, nephropathy requiring dialysis, that would not be expected to be influenced by use of bivalirudin. Presence of a differing outcome between the 2 groups in the absence of biological plausibility would be suggestive of residual confounding. 19 In addition, we performed a sensitivity analysis to evaluate the impact of an unmeasured confounder as previously described. 20 Sensitivity analysis was implemented using the R package Rbounds available at http://cran.r-project.org/web/ packages/rbounds/.
Results
Our study population comprised 64 052 patients who underwent PCI from 2007 to 2009, and of whom, 28 378 were treated with bivalirudin (44%) and 35 674 with heparin and GPIs (56%). Of the 35 674 subjects treated with heparin and GPIs, the majority (34 022; 95%) received eptifibatide, whereas the rest were treated with abciximab. The access choice in the study population was predominantly femoral (98%). Approximately half of our population had some form of renal dysfunction: 19 618 (30%) patients had stage II CKD (GFR, 60-89), 12 087 (19%) had stage III CKD (GFR, 30-59), and 1092 (1.7%) had stage IV CKD (GFR, 15-29).
WHAT IS KNOWN
• Patients with chronic kidney disease and coronary artery disease are known to have an increased incidence of bleeding complications after percutaneous coronary intervention.
• Use of bivalirudin has been associated with a reduction in the incidence of bleeding in patients undergoing percutaneous coronary intervention.
• Patients with more severe degrees of renal dysfunction have often been excluded or under-represented in clinical trials to determine the optimal antithrombotic regimen to use in patients with chronic kidney disease undergoing percutaneous coronary intervention.
WHAT THE STUDY ADDS
• Bivalirudin was associated with a reduced risk of bleeding across all categories of renal dysfunction, with no difference in ischemic complications.
• This study fills an important gap in the evidence base regarding the safety of bivalirudin use in patients with more severe renal insufficiency, specifically those classified as having stage III and stage IV chronic kidney disease. December 2013
In unadjusted analysis, there were multiple significant differences between patients who were treated with bivalirudin compared with those treated with heparin and GPIs (Table 1) . Patients treated with bivalirudin were older, had a lower GFR, and had more comorbidities including hypertension, diabetes mellitus, prior coronary artery disease, and prior coronary revascularization (Table 1) . By comparison, the propensity-matched cohorts were well balanced, with no major difference in baseline characteristics of patients treated with bivalirudin compared with those who received heparin and GPIs (Table 1 ). The distribution of propensity scores was different between the 2 treatment groups ( Figure I in the online-only Data Supplement) because of the difference in patient characteristics. As a result, many patients could not be matched. The final matched cohorts included 15 781 patients in each group.
The unadjusted outcome of patients treated with bivalirudin or heparin and GPIs is provided in Table 2 . In unadjusted analysis, use of bivalirudin was associated with a lower incidence of transfusion, GI bleeding, vascular complications, need for CABG, and death.
In the propensity-matched analysis, the use of bivalirudin was associated with a statistically significant reduction in the number of transfusions (2.8% versus 4.2%; P<0.0001), GI bleeding (0.5% versus 1.3%; P<0.0001), and all vascular complications (1.0% versus 2.5%; P<0.0001), with no difference in major adverse cardiac outcomes other than CABG, which was slightly increased with GPIs ( Table 2) . When the specific subtypes of vascular complications were evaluated, the use of bivalirudin was associated with a statistically significant reduction in hematomas (0.94% versus 2.0%; P<0.0001) and retroperitoneal hematomas (0.15% versus 0.53%; P<0.0001), with no difference in acute thrombosis or loss of limb (Table 2) .
When stratified by CKD class, the risk of bleeding complications after PCI increased with worsening CKD (Figure) . There were fewer transfusions and GI bleeds associated with use of bivalirudin as compared with heparin and GPIs across all categories of renal dysfunction (Figure) . The overall interaction between treatment type and severity of CKD was not statistically significant in regard to transfusions (P=0.79), GI bleeds (P=0.30), or vascular complications (P=0.65), suggesting that the antibleeding efficacy of bivalirudin was preserved and similar across all classes of CKD.
To assess for residual confounding between the 2 groups, the incidence of nephropathy requiring dialysis was evaluated. This is presumed to be causally unrelated to anticoagulation strategy and ideally should not be influenced by use of bivalirudin. No difference in this unrelated outcome was observed (Table 2) . Similarly, contrast-induced nephropathy which was more common in the heparin plus GPI group (3.2% versus 2.1%; P<0.001) in the unmatched analysis did not differ in the matched population (2.6% versus 2.3%; P=0.12). Furthermore, in a sensitivity analysis, the association between bivalirudin use and vascular complications and GI bleed was robust enough to the effect of an unmeasured confounder. The association with transfusion was moderately robust, whereas the results corresponding to CABG were only mildly robust ( Table I in 
Discussion
The key finding of our study is that bivalirudin was associated with a dramatically reduced risk of bleeding across all categories of renal dysfunction, with no difference in ischemic complications. The risk of bleeding complications was higher in patients with more severe CKD, but the bleeding avoidance benefit of bivalirudin was evident across the entire spectrum of renal dysfunction. The results of our study corroborate and significantly extend previous studies that have shown bivalirudin to be superior to heparin and GPIs for bleeding complications and similar to heparin and GPIs with respect to ischemic complications in patients with CKD. [12] [13] [14] [15] Furthermore, our study fills an important gap in the evidence base regarding the safety of bivalirudin use in patients with more severe renal insufficiency, specifically those classified as having stage III and stage IV CKD.
The lower risk of bleeding complications in patients treated with bivalirudin has been demonstrated in multiple randomized as well as observational studies. [6] [7] [8] [9] [10] [11] Data are more limited with respect to the impact of renal function on the safety and efficacy of bivalirudin. Subanalysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial demonstrated that use of bivalirudin monotherapy in patients with CKD resulted in significantly less bleeding with no significant difference in ischemic outcomes, but this study excluded patients with CKD with a creatinine clearance of <30 mL/min (stage IV CKD) and only included 2469 patients with stage III CKD. 13 A subanalysis of the the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial demonstrated similar results, but only included data on 886 patients with creatinine clearances <60 mL/min. 12 Chew et al 14 pooled 5035 patients enrolled in 3 trials and demonstrated that bivalirudin compared with heparin alone provided greater absolute benefit for ischemic and bleeding complications with greater degrees of renal impairment. The authors were able to demonstrate an interaction between the degree of renal impairment and the overall benefit from bivalirudin on an additive scale. We also attempted to assess whether a greater relative level of benefit with bivalirudin was seen in patients with greater degrees of renal impairment. Although the absolute benefit of bivalirudin was greater in patients with advanced kidney disease, we did not observe an interaction between the relative effect of bivalirudin versus heparin and GPIs with respect to bleeding or ischemic complications and CKD severity.
The strengths of our study include our large sample size and the contemporary nature of our data set. We evaluated the outcome of 64 052 patients treated by multiple operators at most of the hospitals providing PCI services in the state of Michigan between 2007 and 2009. In addition, patients with CKD were extremely well represented in our study population with 51% (n=32 880) of the study cohort having some form of renal dysfunction. This is a much larger group of patients than what was assembled for a meta-analysis looking at bivalirudin safety and efficacy in patients with CKD (n=5035). 14 We were also able to look specifically at patients with severe renal impairment, a population that is often underrepresented in clinical trials secondary to the use of restrictive inclusion and exclusion criteria. 13 Roughly, 21% of our population (n=13 179) had stage 3 or 4 CKD, which is higher than the 14% to 15% noted in 2 large randomized trials examining post-PCI bleeding among patients with renal insufficiency. 12, 13 More specifically, we were able to obtain data on 1092 patients with stage IV CKD, a population that has often been excluded from large randomized controlled trials and for which comparative efficacy data are sparse. 13 We also noticed a nonsignificant trend toward an increase in stent thrombosis with bivalirudin. It is possible that our study is underpowered to detect a difference in this complication, although the low event rate in both arms is itself reassuring. Second, an increase in use of CABG was noted among patients treated with GPIs, although this end point was most sensitive to the effect of an unmeasured confounder. Further studies are warranted to assess for any differences in these 2 end points.
Our results should be interpreted with certain caveats. The BMC2-PCI registry is a regional collaborative with a focus on quality improvement and may or may not be representative of the wider population of patients undergoing PCI in the United States. This was an observational study and thus is prone to certain limitations. The study was also subject to unmeasured residual confounding despite propensity-matched analyses. However, our sensitivity analysis suggested that the antibleeding efficacy estimates were fairly robust to the presence of an unmeasured confounder and are likely extant. In addition, data were not collected on the dosing used for the various antithrombotic agents, thus we cannot be sure that medication dosage was adjusted for renal function. Finally, renal insufficiency was defined using the calculated GFR at presentation, and the duration of renal insufficiency was not known. This limits the ability to account for acute changes in renal function before admission or that may have occurred as a consequence of the event causing admission. 4
Conclusions
The risk of bleeding after PCI rises with worsening CKD. Bivalirudin was associated with a dramatically reduced risk Unmatched and matched outcomes of patients who received either bivalirudin or GPI during PCI are presented. CABG indicates coronary artery bypass grafting; GI, gastrointestinal; GPI, glycoprotein IIb/IIIa inhibitor; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; Q MI, Q wave myocardial infarction; and TIA, transient ischemic attack.
Figure.
Propensity-matched odds of transfusion and gastrointestinal bleeding in patients treated with bivalirudin versus glycoprotein IIb/IIIa inhibitor (GPI) stratified by stage of chronic kidney disease. GFR indicates glomerular filtration rate.
of bleeding across all categories of renal dysfunction. These findings further support bivalirudin monotherapy as an acceptable, if not the more appropriate alternative, to GPIs in patients with CKD.
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